TERM ID="NYU_TERM_1" STRING="CHB" FREQUENCY=1 START=247 END=250 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_2" STRING="Clinical Excellence" FREQUENCY=1 START=356 END=375 LEMMA="CLINICAL EXCELLENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="DNA reduction" FREQUENCY=1 START=1058 END=1071 LEMMA="DNA REDUCTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="HBV" FREQUENCY=1 START=1053 END=1056 LEMMA="HEPATITIS B VIRUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_5" STRING="HBV DNA non-detectability" FREQUENCY=1 START=1073 END=1098 LEMMA="HBV DNA NON-DETECTABILITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="HBeAg loss" FREQUENCY=1 START=1274 END=1284 LEMMA="HBEAG LOSS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="HBeAg-negative patients" FREQUENCY=1 START=886 END=909 LEMMA="HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="HBeAg-positive patients" FREQUENCY=2 START=1157 END=1180 LEMMA="HBEAG-POSITIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_9" STRING="HBeAg-positive patients" FREQUENCY=2 START=1185 END=1208 LEMMA="HBEAG-POSITIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_10" STRING="HBeAg-positive patients/HBeAg-negative patients" FREQUENCY=2 START=2036 END=2083 LEMMA="HBEAG-POSITIVE PATIENTS/HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_11" STRING="HBeAg-positive patients/HBeAg-negative patients" FREQUENCY=2 START=2367 END=2414 LEMMA="HBEAG-POSITIVE PATIENTS/HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_12" STRING="ICER" FREQUENCY=2 START=2229 END=2233 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_13" STRING="ICER" FREQUENCY=2 START=2493 END=2497 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_14" STRING="ICERs" FREQUENCY=1 START=2360 END=2365 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIOS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="QALY" FREQUENCY=3 START=2169 END=2173 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_16" STRING="QALY" FREQUENCY=3 START=2267 END=2271 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_17" STRING="QALY" FREQUENCY=3 START=2530 END=2534 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_18" STRING="QALY gain" FREQUENCY=1 START=2472 END=2481 LEMMA="QALY GAIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="RCT" FREQUENCY=2 START=510 END=513 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_20" STRING="RCT" FREQUENCY=2 START=609 END=612 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_21" STRING="RCTs comparing entecavir" FREQUENCY=1 START=1390 END=1414 LEMMA="RCTS COMPARING ENTECAVIR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="Resubmitted results" FREQUENCY=1 START=2274 END=2293 LEMMA="RESUBMITTED RESULT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="STA" FREQUENCY=1 START=427 END=430 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_24" STRING="STA states" FREQUENCY=1 START=3095 END=3105 LEMMA="STA STATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="Telbivudine" FREQUENCY=1 START=0 END=11 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_26" STRING="addition" FREQUENCY=1 START=2937 END=2945 LEMMA="ADDITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="adefovir" FREQUENCY=2 START=1754 END=1762 LEMMA="ADEFOVIR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_28" STRING="adefovir" FREQUENCY=2 START=2635 END=2643 LEMMA="ADEFOVIR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_29" STRING="alanine aminotransferase" FREQUENCY=1 START=1103 END=1127 LEMMA="ALANINE AMINOTRANSFERASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="antiviral outcomes" FREQUENCY=1 START=2867 END=2885 LEMMA="ANTIVIRAL OUTCOME" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="chronic hepatitis B" FREQUENCY=3 START=226 END=245 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_32" STRING="chronic hepatitis B" FREQUENCY=3 START=226 END=245 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_33" STRING="chronic hepatitis B" FREQUENCY=3 START=3163 END=3182 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_34" STRING="chronic hepatitis B infection" FREQUENCY=1 START=33 END=62 LEMMA="CHRONIC HEPATITIS B INFECTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="clarification" FREQUENCY=1 START=2314 END=2327 LEMMA="CLARIFICATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="clinical effectiveness" FREQUENCY=1 START=144 END=166 LEMMA="CLINICAL EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_37" STRING="clinicians" FREQUENCY=1 START=3295 END=3305 LEMMA="CLINICIAN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="comparing telbivudine" FREQUENCY=1 START=560 END=581 LEMMA="COMPARING TELBIVUDINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="controlled trial" FREQUENCY=1 START=492 END=508 LEMMA="CONTROLLED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_40" STRING="cost-effective option" FREQUENCY=2 START=1947 END=1968 LEMMA="COST-EFFECTIVE OPTION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_41" STRING="cost-effective option" FREQUENCY=2 START=2586 END=2607 LEMMA="COST-EFFECTIVE OPTION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_42" STRING="cost-effectiveness" FREQUENCY=2 START=171 END=189 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_43" STRING="cost-effectiveness" FREQUENCY=2 START=1620 END=1638 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_44" STRING="cost-effectiveness evidence" FREQUENCY=1 START=2951 END=2978 LEMMA="COST-EFFECTIVENESS EVIDENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_45" STRING="cost-effectiveness of telbivudine" FREQUENCY=2 START=171 END=204 LEMMA="TELBIVUDINE COST-EFFECTIVENESS" LEMMA_FREQUENCY=2 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_46" STRING="cost-effectiveness of telbivudine" FREQUENCY=2 START=1620 END=1653 LEMMA="TELBIVUDINE COST-EFFECTIVENESS" LEMMA_FREQUENCY=2 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_47" STRING="critical assessment" FREQUENCY=1 START=1808 END=1827 LEMMA="CRITICAL ASSESSMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_48" STRING="developed resistance" FREQUENCY=1 START=2667 END=2687 LEMMA="DEVELOPED RESISTANCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_49" STRING="economic models" FREQUENCY=1 START=1587 END=1602 LEMMA="ECONOMIC MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_50" STRING="evidence review group" FREQUENCY=1 START=100 END=121 LEMMA="EVIDENCE REVIEW GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_51" STRING="first-line" FREQUENCY=1 START=2691 END=2701 LEMMA="FIRST-LINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_52" STRING="first-line telbivudine treatment" FREQUENCY=1 START=2691 END=2723 LEMMA="TELBIVUDINE TREATMENT FIRST-LINE" LEMMA_FREQUENCY=1 HEAD_TERM="telbivudine treatment" HEAD_LEMMA="TELBIVUDINE TREATMENT"
TERM ID="NYU_TERM_53" STRING="hepatitis B e antigen (HBeAg)-positive patients" FREQUENCY=1 START=817 END=864 LEMMA="HEPATITIS B E ANTIGEN (HBEAG)-POSITIVE PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_54" STRING="hepatitis B virus" FREQUENCY=1 START=1034 END=1051 LEMMA="HEPATITIS B VIRUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_55" STRING="including hepatitis B virus" FREQUENCY=1 START=1024 END=1051 LEMMA="INCLUDING HEPATITIS B VIRUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_56" STRING="inclusion criteria" FREQUENCY=1 START=639 END=657 LEMMA="INCLUSION CRITERION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_57" STRING="incremental cost" FREQUENCY=2 START=2090 END=2106 LEMMA="INCREMENTAL COST" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_58" STRING="incremental cost" FREQUENCY=2 START=2421 END=2437 LEMMA="INCREMENTAL COST" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_59" STRING="incremental cost-effectiveness ratio" FREQUENCY=2 START=2191 END=2227 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_60" STRING="incremental cost-effectiveness ratio" FREQUENCY=2 START=2191 END=2227 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_61" STRING="lamivudine" FREQUENCY=4 START=587 END=597 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_62" STRING="lamivudine" FREQUENCY=4 START=1420 END=1430 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_63" STRING="lamivudine" FREQUENCY=4 START=1699 END=1709 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_64" STRING="lamivudine" FREQUENCY=4 START=1983 END=1993 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_65" STRING="life-year" FREQUENCY=1 START=2158 END=2167 LEMMA="LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_66" STRING="manufacturer" FREQUENCY=5 START=288 END=301 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_67" STRING="manufacturer" FREQUENCY=5 START=1560 END=1572 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_68" STRING="manufacturer" FREQUENCY=5 START=1902 END=1914 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_69" STRING="manufacturer" FREQUENCY=5 START=2541 END=2553 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_70" STRING="manufacturer" FREQUENCY=5 START=3011 END=3024 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_71" STRING="methodological quality" FREQUENCY=1 START=537 END=559 LEMMA="METHODOLOGICAL QUALITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_72" STRING="methodological quality comparing telbivudine" FREQUENCY=1 START=537 END=581 LEMMA="COMPARING TELBIVUDINE METHODOLOGICAL QUALITY" LEMMA_FREQUENCY=1 HEAD_TERM="comparing telbivudine" HEAD_LEMMA="COMPARING TELBIVUDINE"
TERM ID="NYU_TERM_73" STRING="presentation" FREQUENCY=1 START=2738 END=2750 LEMMA="PRESENTATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_74" STRING="primary outcome" FREQUENCY=1 START=700 END=715 LEMMA="PRIMARY OUTCOME" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_75" STRING="primary outcome of therapeutic response telbivudine" FREQUENCY=1 START=700 END=751 LEMMA="THERAPEUTIC RESPONSE TELBIVUDINE PRIMARY OUTCOME" LEMMA_FREQUENCY=1 HEAD_TERM="primary outcome" HEAD_LEMMA="PRIMARY OUTCOME"
TERM ID="NYU_TERM_76" STRING="randomised controlled trial" FREQUENCY=1 START=481 END=508 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_77" STRING="receiving telbivudine" FREQUENCY=1 START=3209 END=3230 LEMMA="RECEIVING TELBIVUDINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_78" STRING="secondary outcomes" FREQUENCY=1 START=994 END=1012 LEMMA="SECONDARY OUTCOME" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_79" STRING="seroconversion" FREQUENCY=1 START=1288 END=1302 LEMMA="SEROCONVERSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_80" STRING="single technology appraisal" FREQUENCY=1 START=398 END=425 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_81" STRING="technology appraisal" FREQUENCY=1 START=405 END=425 LEMMA="TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_82" STRING="telbivudine" FREQUENCY=8 START=193 END=204 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_83" STRING="telbivudine" FREQUENCY=8 START=973 END=984 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_84" STRING="telbivudine" FREQUENCY=8 START=1642 END=1653 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_85" STRING="telbivudine" FREQUENCY=8 START=1683 END=1694 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_86" STRING="telbivudine" FREQUENCY=8 START=1930 END=1941 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_87" STRING="telbivudine" FREQUENCY=8 START=2569 END=2580 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_88" STRING="telbivudine" FREQUENCY=8 START=2805 END=2816 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_89" STRING="telbivudine" FREQUENCY=8 START=3111 END=3122 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=9
TERM ID="NYU_TERM_90" STRING="telbivudine treatment" FREQUENCY=1 START=2702 END=2723 LEMMA="TELBIVUDINE TREATMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_91" STRING="therapeutic response telbivudine" FREQUENCY=1 START=719 END=751 LEMMA="THERAPEUTIC RESPONSE TELBIVUDINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_92" STRING="time point" FREQUENCY=1 START=1310 END=1320 LEMMA="TIME POINT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_93" STRING="treatment groups" FREQUENCY=1 START=1253 END=1269 LEMMA="TREATMENT GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_94" STRING="treatment groups for HBeAg loss" FREQUENCY=1 START=1253 END=1284 LEMMA="HBEAG LOSS TREATMENT GROUP" LEMMA_FREQUENCY=1 HEAD_TERM="treatment groups" HEAD_LEMMA="TREATMENT GROUP"
TERM ID="NYU_TERM_95" STRING="viral load model" FREQUENCY=1 START=2018 END=2034 LEMMA="VIRAL LOAD MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_96" STRING="week" FREQUENCY=1 START=873 END=877 LEMMA="WEEK" LEMMA_FREQUENCY=1
